Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Journal Pre-proof



Clinical Characteristics of COVID-19 in Osaka, Japan: Comparison of the First–Third Waves with the Fourth Wave

Yu Kurahara, Takehiko Kobayashi, Sayoko Shintani, Yoshinobu Matsuda, Akihiro Tamiya, Reiko Sugawara, Toru Arai, Kazunobu Tachibana, Kyoichi Okishio, Hideo Matsui, Kazunari Tsuyuguchi

PII: S2212-5345(21)00150-7

DOI: https://doi.org/10.1016/j.resinv.2021.08.005

Reference: RESINV 700

To appear in: *Respiratory Investigation*

Received Date: 1 August 2021

Revised Date: 12 August 2021

Accepted Date: 21 August 2021

Please cite this article as: Kurahara Y, Kobayashi T, Shintani S, Matsuda Y, Tamiya A, Sugawara R, Arai T, Tachibana K, Okishio K, Matsui H, Tsuyuguchi K, Clinical Characteristics of COVID-19 in Osaka, Japan: Comparison of the First–Third Waves with the Fourth Wave, *Respiratory Investigation*, https://doi.org/10.1016/j.resinv.2021.08.005.

Clinical Characteristics of COVID-19 in Osaka, Japan: Comparison of the First–Third Waves with the Fourth Wave

Yu Kurahara[a,b], Takehiko Kobayashi[a], Sayoko Shintani[a], Yoshinobu Matsuda[c], Akihiro Tamiya[a], Reiko Sugawara[a], Toru Arai[a,d], Kazunobu Tachibana[a,d], Kyoichi Okishio[d], Hideo Matsui[a], Kazunari Tsuyuguchi[a,b,d]*

[a]Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.

[b]Department of Infectious Diseases, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.

[c]Department of Psychosomatic Internal Medicine and Supportive and Palliative Care Team, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.

[d]Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.

*Corresponding author

Word count of Abstract: 249 words

Word count of Text: 2819 words

Correspondence to:

Kazunari Tsuyuguchi, MD

Department of Infectious Diseases, Internal Medicine, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-Cho, Kita-Ku, Sakai City, Osaka, 591-8555, Japan

Phone: +81-72-252-3021

Fax: +81-72-251-1372

E-mail: tsuyuguchi.kazunari.ky@mail.hosp.go.jp

Abstract

***Background*:** The fourth wave of COVID-19 in Osaka Prefecture, Japan, caused a medical crisis. Here, we aim to identify the risk factors for COVID-19 severity and compare patients between the first–third waves and the fourth wave.

Methods: We performed an observational retrospective study of COVID-19 cases at the National Hospital Organization Kinki-Chuo Chest Medical Center.

Results: We identified 404 patients (median age: 71.0 years [interquartile range: 56.0–80.0]), of whom 199 (49.1%) had mild disease, 142 (35.2%) had moderate disease, and 63 (15.6%) had severe disease. The overall mortality rate was 5.4% (22/404). Based on multivariate logistic regression analysis, cardiovascular disease, fever, dyspnea, and several inflammatory biomarkers were independent risk factors for moderate to severe disease. For every 1 mg/dL increase in C-reactive protein, 10 IU/L increase in lactate dehydrogenase, and 100 ng/mL increase in ferritin, the risk for moderate to severe disease increased by 18.3%, 12.9%, and 8.9%, respectively. Overall disease severity in the fourth wave was higher than in the first–third waves. However, there was no significant difference in mortality. Because of a shortage of beds, four of the 28 severe patients (14.3%) in the fourth wave could not be transferred to the advanced hospital.

Conclusions: Cardiovascular disease, fever, dyspnea, and several inflammatory biomarkers were risk factors for moderate to severe COVID-19 in our cohort. During the

fourth wave, COVID-19 severity worsened, increasing the number of patients who could not be transferred to beds for severe cases, resulting in a medical crisis in Osaka.

Keywords: clinical characteristics, COVID-19, Osaka, fourth wave, medical crisis

Abbreviations

ALT: alanine aminotransferase

AST: aspartate aminotransferase

COPD: chronic obstructive pulmonary disease

COVID-19: coronavirus disease 2019

CRP: C-reactive protein

CI: confidence interval

ICU: intensive care unit

IQR: interquartile range

KL-6: Krebs von den Lungen-6

LDH: lactate dehydrogenase

OR: odds ratio

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

VOC: variant of concern

WBC: white blood cell

1. Introduction

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection (coronavirus disease 2019, abbreviated as COVID-19) was confirmed in Wuhan, China, in December 2019, and the pandemic has since spread around the world [1]. A clinical characteristic of COVID-19 is its diverse presentation, ranging from asymptomatic to fatal. The risk of severe disease and mortality may differ based on population, period, and region. For example, there were differences in the number of patients per wave of infections even in cities with similar population sizes. Severity and mortality also differed between waves in Osaka [2], and in Sapporo patient characteristics differed between two waves [3].

Osaka Prefecture is the largest metropolitan area in western Japan, with a population of 8.82 million. As of June 2021, it had experienced four waves of infections in the COVID-19 pandemic, in the following periods: January 29 to June 13, 2020; June 14 to October 9, 2020; October 10, 2020 to February 28, 2021; and March 1, 2021 until the time of writing (**Figure 1**). The Japanese government declared a state of emergency three times in Osaka Prefecture, on April 7, 2020, January 13, 2021, and April 25, 2021. This declaration called on people in the area to strictly observe prevention measures including refraining from traveling, early closure requests for restaurants, and encouraging remote working. Despite this, the fourth wave briefly caused a medical crisis because beds for severe cases were at maximum capacity, restricting the transfer of some patients to

advanced hospitals.

In the present study, we aimed to identify factors influencing COVID-19 severity and assess any differences in COVID-19 patients between the first–third waves and the fourth wave of infections. Finally, we assessed the factors leading to the medical crisis in Osaka.

2. Materials and methods

2.1. Study Subjects

We performed a single-center retrospective observational study with patients from the National Hospital Organization Kinki-Chuo Chest Medical Center, a respiratory disease center designed to manage patients with mild to moderate COVID-19 symptoms. If patients' condition turned severe and needed mechanical ventilation, they were transferred to an advanced hospital.

We retrospectively assessed all consecutive COVID-19 patients admitted to the hospital between 1 March 2020 and 8 June 2021. In addition, we compared the clinical patterns of COVID-19 patients between the first–third waves and the fourth wave.

The severity of the COVID-19 infection at admission was defined by the guidelines on the clinical management of patients with COVID-19 and criteria for Osaka prefecture. Mild cases were defined as those not requiring oxygen administration, moderate cases were those who did require oxygen administration, and severe cases were those requiring mechanical ventilation or extracorporeal membrane oxygenation, or those admitted to the intensive care unit (ICU). Disease severity was defined as the most severe condition recorded during hospitalization. The treatment strategy followed the official Japanese guidelines developed by the Ministry of Health, Labour, and Welfare [4].

COVID-19 diagnosis was confirmed by a polymerase chain reaction test or an

antigen test for SARS-CoV-2 from saliva, sputum, or nasopharyngeal swabs. The end of the follow-up period was defined as the date of discharge, transfer to the advanced hospital, or death.

We collected the following data: age, sex, disease severity, presence of infection cluster, smoking history, comorbidities, clinical manifestations, laboratory data at admission, treatment, and outcome. Comorbidities included hypertension, cardiovascular diseases (coronary heart diseases, cerebrovascular diseases, peripheral arterial diseases, and deep vein thromboses), diabetes, dementia, chronic kidney disease, underlying pulmonary conditions, malignant diseases, and connective tissue diseases. Laboratory data included white blood cell (WBC) count, lymphocyte count, C-reactive protein (CRP), D-dimer, lactate dehydrogenase (LDH), albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), ferritin, and Krebs von den Lungen-6 (KL-6) at admission. Fever was defined as a measured temperature of 38 °C or greater. We defined a cluster as >5 cases with primary exposure reported at a common event or venue, excluding within-household transmissions.

Publicly available information on the patients was collected from the Osaka prefecture website [5].

This study was approved by the institutional review board of the Kinki-Chuo Chest Medical Center (#795, approval date: 16/JUL/2021). We used an opt-out method that

enabled patients and their families to refuse to participate in the study if they wished.

2.2. Infection control policies of Osaka Prefecture during the first–fourth waves

The first COVID-19 case in Osaka was detected on January 29, 2020. On April 7, the Japanese government declared a state of emergency, which was lifted on May 21. Daily new cases decreased following the first wave. Although cases had begun to increase again by mid-June 2020, the government did not declare a state of emergency. The third wave began in October 2020. The government declared a state of emergency for the second time on January 7, 2021, after which the cases decreased. However, they began to increase again in April 2021 (**Figure 1**). During the fourth wave, Osaka's healthcare system became increasingly overwhelmed, with hospitals running out of beds and ventilators. For example, some patients could not be transferred to the hospital for severe cases. In addition, some mild patients who were still at home or in designated accommodation died when their condition worsened rapidly and they could not be hospitalized.

2.3. Statistical analysis

Continuous data are presented as median and interquartile range (IQR), and categorical data are presented as frequencies and proportions. We used Wilcoxon rank-sum tests for nonparametric continuous variables and Pearson's chi-squared tests for

categorical variables.

We searched for candidate risk factors for moderate to severe COVID-19 by stratifying the patients based on five categories: patient factors, habits/behaviors, underlying disease, symptoms at admission, and laboratory data. Patient factors were age and sex; habits/behavior was infection from a cluster and smoking history; underlying disease categories were hypertension, cardiovascular diseases, diabetes, dementia, chronic kidney disease, underlying pulmonary conditions, malignant diseases, and connective tissue diseases; symptoms at admission were fever, cough, dyspnea, sputum, fatigue, diarrhea, and anorexia; and laboratory data comprised WBC count, lymphocytes, CRP, D-dimer, albumin, AST, ALT, LDH, ferritin, and KL-6. We used logistic regression analysis to calculate odds ratios (OR) and their 95% confidence intervals (CI). Laboratory test results were converted to clinically useful units and used as explanatory variables; for example, WBC count was expressed as 100/μL.

For our multivariate analyses, we selected covariates according to the modified Disjunctive Cause Criterion, to adjust for confounding factors [6]. As a result, for habits/behavior and underlying disease, we used only patient factors as covariates, whereas for symptoms and laboratory test results at admission, we used all three remaining categories as covariates. In other words, the confounding candidates used to calculate the adjusted ORs were different for each variable. For example, to calculate the OR adjusted

for hypertension, we adjusted for the two variables patient characteristics (age and sex), and to calculate the OR adjusted for fever, we adjusted for the following 12 variables: patient characteristics (age and sex), patient habits and behaviors (infection from a cluster and smoking history), and underlying disease (hypertension, cardiovascular diseases, diabetes, dementia, chronic kidney disease, underlying pulmonary conditions, malignant diseases, connective tissue diseases). All *P*-values were two-sided and a *P*-value of < 0.05 was considered statistically significant. All statistical analyses were performed using Stata/MP version 16.1 (StataCorp, College Station, TX, USA).

3. Results

3.1. Characteristics and clinical features of COVID-19 patients

We identified 404 COVID-19 patients (**Table 1**). The median age of the patients was 71.0 years (IQR: 56.0–80.0), with 342 (59.9%) males and 162 (40.1%) females. Of these, 46 (11.4%) had been infected from a cluster. With respect to case severity, 199 patients (49.1%) had mild disease, 142 (35.2%) had moderate disease, and 63 (15.6%) had severe disease. The most common comorbidities were hypertension (176, 43.6%), diabetes (91, 22.5%), and underlying pulmonary condition (86, 21.3%). Of 86 patients with underlying pulmonary condition, 65 had chronic obstructive pulmonary disease (COPD), ten had asthma, six had interstitial lung diseases, two had asthma and COPD overlap, two had lung cancer, and one patient had pneumoconiosis. After excluding missing data, the median duration from onset to hospitalization in 388 patients was 6 days (IQR: 4-8), with no significant differences observed by severity of the disease. Remdesivir in addition to systemic corticosteroids was the most commonly administered treatment for moderate and severe patients. Tocilizumab or baricitinib were used in cases of suspected cytokine release syndrome. The overall mortality rate was 5.4% (22/404).

We identified risk factors for acute respiratory failure requiring oxygenation (namely, moderate and severe cases) (**Table 2**). The univariate logistic regression analysis showed that infection from a cluster and dementia were associated with significantly lower ORs for

moderate to severe disease, at 0.302 and 0.429, respectively. ~~This was because most of the admissions from elderly facility clusters were mild cases.~~ Conversely, smoking, cardiovascular disease, fever, and dyspnea were associated with significantly higher ORs, 1.635, 3.466, 2.788, and 2.935, respectively. All laboratory data except lymphocytes and albumin were significantly associated with moderate to severe disease risk (OR point estimates: 1.010–1.208). However, even though WBC count, albumin, AST, and ALT were statistically significant, their OR point estimates were close to 1 (1.010–1.021).

In our multivariate analyses, smoking was not significant (OR 1.522, $P = 0.070$), but the results for the other variables were similar to those in the univariate analysis. Cardiovascular disease, fever, and dyspnea were associated with significantly higher ORs, 3.722, 2.853, and 2.507, respectively. All laboratory data other than lymphocytes and albumin were significant (OR point estimates: 1.012–1.254). For every 1 mg/dL increase in CRP, 10 IU/L increase in LDH, and 100 ng/mL increase in ferritin, the risk for moderate to severe disease increased by 18.3%, 12.9%, and 8.9%, respectively.

3.2. The first–third waves vs. the fourth wave

Overall disease severity in the fourth wave was higher than that in the first–third waves (**Table 3**). During the fourth wave, the number of mild cases halved, whereas moderate cases doubled. The proportion of moderate cases, particularly those in the 50–80

age group, increased (**Figure 2**). With respect to the laboratory data, CRP, AST, LDH, and ferritin were significantly higher in fourth-wave patients than in first–third-wave patients ($P < 0.01$ for all). There were fewer cases of infection from a cluster than in the first–third waves (16.2% vs. 4.3%, $P < 0.01$). There were no fully-vaccinated patients in the present study.

During the fourth wave, remdesivir and systemic corticosteroids were widely used, based on previous efficacy (**Table 3**) [7, 8]. Conversely, favipiravir was used less frequently, because of a lack of effective treatment evidence.

In the prefecture, the waiting list for beds for severe patients briefly reached a maximum of 94 (**Figure 3**). Therefore, four of the 28 severe patients (14.3%) in our hospital could not be transferred to the advanced hospital during the fourth wave. These patients received mechanical ventilation for 2, 3, 9, and 12 days, and recovered. There was no difference in mortality between the first–third waves and the fourth wave (5.4% vs. 5.5%, $P = 0.80$).

4. Discussion

COVID-19 in patients with underlying medical conditions induced pneumonia with elevated inflammatory biomarkers. In Osaka, we observed many moderate to severe cases in the fourth wave.

We identified several inflammatory biomarkers as independent risk factors for moderate to severe disease. For example, for every 1 mg/dL increase in CRP, the risk for moderate to severe disease increased by 18.3% in our cohort. Similarly, for every 10 IU/L increase in LDH and 100 ng/mL increase in ferritin, the risk increased by 12.9% and 8.9%, respectively. Studies in Kanagawa prefecture [9] also reported that CRP was a risk factor for moderate (requiring > 1–4 L/min of oxygen) to severe (requiring > 5 L/min of oxygen) disease. In the fourth wave, pneumonia caused by the variant of concern (VOC) resulted in severe inflammation, and many of the cases with high CRP levels suffered respiratory failure.

There were more moderate cases in the fourth wave than in the first–third waves (49.7% vs. 25.3%). However, we observed no significant increase in mortality (5.5% vs. 5.4%). The reasons could be as follows: the COVID-19 prognosis appears to be positive if the patient survives the respiratory failure phase, and evidence for the therapeutic efficacy of treatments such as systemic corticosteroids and remdesivir administration has been accumulating [7, 8]. In our study, systemic corticosteroids were administered to the 39.7%

of mild cases who exhibited extensive ground-glass shadows in both lungs, since this was projected to result in respiratory failure within a few days. Since patient treatment and outcome after transfer to the advanced hospital was not included in our cohort, it is possible that there was a difference in the actual mortality rate. However, data from Osaka prefecture reported that there was no difference in mortality between the third and fourth waves (2.6% vs. 2.8%; denominator is all SARS-CoV-2 positive subjects) [5], which supports the validity of our data.

In contrast to the first–third waves, the fourth wave saw a rapid increase in cases, and 66.9% of the fourth-wave patients in our cohort experienced acute respiratory failure (moderate to severe). The proportion of patients requiring oxygen administration was 1.7 times higher than in the first–third waves. This resulted in a shortage of available medical staff and of beds for severe cases. The number of ICU beds in Osaka Prefecture was originally 618, of which COVID-19 patients occupied an unanticipated 75%. This caused non-COVID-19 medical services, such as emergency medicine and surgery, to halt temporarily. In the prefecture, the waiting list for beds for severe patients briefly reached a maximum of 94 (**Figure 3**). Therefore, the fourth COVID-19 wave in Osaka triggered a medical crisis, where mild to moderate cases could no longer be transferred to the advanced hospital after worsening and patients at home or in designated accommodations could not be admitted to any hospital. The elderly COVID-19 patients had to be cared for in

a nursing home. Therefore, there were fewer cases of infection from clusters in the fourth wave than in the first–third waves in our cohort (16.2% vs. 4.3%, $P < 0.01$). This led to some patient deaths at home or nursing home in the fourth wave.

At the end of the third wave, the state of emergency was lifted in Osaka three weeks earlier than in the Tokyo region, where a VOC may have accounted for a rising proportion of new infections. Osaka may have been the epicenter of cases with the alpha VOC (lineage B.1.1.7), which is more infectious and led to more severe disease in the fourth wave. The B.1.1.7 variant accounted for 82% of the positive cases screened by the health center during the fourth wave [4]. Observational studies [10, 11] and a retrospective cohort analysis [12] using a large database from the United Kingdom reported that the risk of death associated with the B.1.1.7 variant is 55–64% higher than that of the original strain. In addition, observational studies conducted in Europe [13, 14] showed that the B.1.1.7 variant is associated with a higher risk of hospitalization than the conventional strain. In the present study, patients in the fourth wave were more likely to suffer from acute respiratory failure, which may be explained by the B.1.1.7 variant.

Our study has several limitations. First, whether the B.1.1.7 variant of SARS-CoV-2 was responsible for the disease severity in the fourth wave is unclear from our data, because the relevant diagnostic test of variants was not available at our hospital. Second, admission to the beds for mild to moderate cases may have been requested only for much

more severe cases in the fourth wave, introducing a potential sampling bias. Third, as mentioned above, since our hospital managed only mild to moderate cases, patient treatment and outcome after transfer to the advanced hospital is not included in the present study, because we used data only from our own hospital. Fourth, this was a single-center study and does not directly reflect overall bed management for COVID-19 in Osaka prefecture. Nevertheless, it can be assumed that, similar to our hospital, several hospitals in Osaka would have experienced a bed shortage for COVID-19 patients.

5. Conclusions

Based on multivariate logistic regression analysis, cardiovascular disease, fever, dyspnea, and several inflammatory biomarkers were risk factors for moderate to severe COVID-19 in our cohort.

During the fourth wave in Osaka prefecture, COVID-19 severity was higher than in the first–third waves, resulting in a medical crisis in which a large number of patients could not be transferred to the advanced hospital for severe cases. At its peak, 20% of severely ill patients were managed at hospitals for mild to moderate cases, resulting in a staffing shortage throughout Osaka. In addition, hospital admissions for patients at home or in designated accommodations were delayed.

In future, emerging infectious diseases may become more common in urban areas in general. Securing hospital beds in the event of widespread diseases that require advanced medical care is a major issue that should be resolved.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

Y.K. contributed to the investigation, data curation, and writing of the original draft. K. Tsuyuguchi contributed to the planning and editing of the article. T.K., S.S., Y.M., A.T., R.S., T.A., K. Tachibana, K.O., and H.M. contributed to the supervision and editing of the article. All authors commented on draft versions and approved the final version.

References

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382:727-33.

[2] Takeuchi T, Kitamura T, Hirayama A, Katayama Y, Shimazu T, Sobue T. Characteristics of patients with novel coronavirus disease (COVID-19) during the first surge versus the second surge of infections in Osaka Prefecture, Japan. Glob Health Med. 2021;3:82-9.

[3] Hattori T, Saito A, Chiba H, Kuronuma K, Amishima M, Morinaga D, et al. Characteristics of COVID-19 patients admitted into two hospitals in sapporo, Japan: Analyses and insights from two outbreak waves. Respir Investig. 2021;59:180-6.

[4] Clinical Management of Patients with COVID-19. A guide for front-line health care workers. https://www.mhlw.go.jp/content/000785119.pdf [Accessed 8 July 2021.]

[5] Osaka Prefectural Government. The Press Releases and Documents about COVID-19 Patients. http://www.pref. osaka.lg.jp/iryo/osakakansensho/corona.html (accessed July 8, 2021) (in Japanese).

[6] VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol. 2019;34:211-219.

[7] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383:1813-26.

[8] RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384:693-704.

[9] Otoshi R, Hagiwara E, Kitayama T, Yamaya T, Higa K, Murohashi K, et al. Clinical characteristics of Japanese patients with moderate to severe COVID-19. J Infect Chemother. 2021;27:895-901.

[10] Davies NG, Jarvis CI, CMMID COVID-19 Working Group; Edmunds WJ, Jewell NP, Daiz-Ordaz K, Keogh RH. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021 ;593:270-4.

[11] Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579.

[12] Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ 2021; 373:n1412.

[13] Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill. 2021;26:2100348.

[14] Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Michaelsen TY,

et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis.2021; S1473-3099(21)00290-5.

Table 1. Characteristics of patients with COVID-19 (N = 404)

	Total (N = 404)	Mild (N = 199)	Moderate (N = 142)	Severe/Death (N = 63)
Patient characteristics				
Age, years	71.0 (56.0-80.0)	72.0 (55.0-82.0)	69.0 (56.3-78.0)	71.0 (61.0-82.5)
Sex, female (%)	162 (40.1%)	89 (44.7%)	55 (38.7%)	18 (28.6%)
Patient habits and behaviors				
Infection from a cluster	46 (11.4%)	34 (17.1%)	9 (6.3%)	3 (4.8%)
Smoking history (current- or ex-smoker)	133 (32.9%)	54 (27.1%)	45 (31.7%)	34 (54.0%)
Underlying disease				
Hypertension	176 (43.6%)	90 (45.2%)	63 (44.4%)	23 (36.5%)
Cardiovascular disease	30 (7.4%)	7 (3.5%)	16 (11.3%)	7 (11.1%)
Diabetes	91 (22.5%)	39 (19.6%)	37 (26.1%)	15 (23.8%)
Dementia	79 (19.6%)	52 (26.1%)	16 (11.3%)	11 (17.5%)
Chronic kidney disease*	31 (7.7%)	12 (6.0%)	8 (5.6%)	11 (17.5%)
Underlying pulmonary condition	86 (21.3%)	38 (19.1%)	32 (22.5%)	16 (25.4%)
Malignant disease	24 (5.9%)	8 (4.0%)	9 (6.3%)	7 (11.1%)
Connective tissue disease	12 (3.0%)	6 (3.0%)	4 (2.8%)	2 (3.2%)
Symptoms at admission				
Fever	350 (86.6%)	161 (80.9%)	128 (90.1%)	61 (96.8%)

Cough	175 (43.3%)	80 (40.2%)	69 (48.6%)	26 (41.3%)
Dyspnea	218 (54.0%)	81 (40.7%)	93 (65.5%)	44 (69.8%)
Sputum	38 (9.4%)	14 (7.0%)	19 (13.4%)	5 (7.9%)
Fatigue	132 (32.7%)	66 (33.2%)	45 (31.7%)	21 (33.3%)
Diarrhea	18 (4.5%)	7 (3.5%)	10 (7.0%)	1 (1.6%)
Anorexia	74 (18.3%)	34 (17.1%)	28 (19.7%)	12 (19.0%)
Laboratory data at admission				
WBC count (/μL)	5,600 (4,300-7,300)	5,200 (4,100-6,500)	6,100 (4,525-7,900)	6,000 (4,800-8,450)
Lymphocytes (/μL)	900 (700-1,200)	1,000 (750-1,200)	800 (600-1,175)	800 (6,000-1,100)
CRP (mg/dL)	5.7 (2.3-10.5)	3.1 (1.2-6.6)	8.0 (4.0-12.4)	10.6 (6.9-15.0)
D-dimer (μg/mL)	1.3 (1.0-1.9)	1.1 (0.8-1.6)	1.4 (1.1-2.0)	1.7 (1.3-3.2)
Albumin (g/dL)	3.5 (3.2-3.9)	3.7 (3.3-4.1)	3.4 (3.0-3.6)	3.3 (3.1-3.7)
AST (IU/L)	38.0 (27.0-58.0)	29.0 (23.0-40.0)	44.0 (32.0-63.0)	54.5 (35.5-71.3)
ALT (IU/L)	27.0 (16.0-46.0)	21.0 (14.0-36.0)	32.5 (20.0-65.5)	34.0 (22.0-56.0)
LDH (IU/L)	313.0 (237.5-408.0)	250.0 (206.5-317.5)	364.5 (301.8-449.0)	427.0 (339.0-529.5)
Ferritin (ng/mL)	576.7 (247.1-1013.0)	337.5 (144.1-728.8)	743.0 (391.9-1430.1)	851.7 (663.6-1531.0)
KL-6 (U/mL)	336.1 (211.0-384.0)	248.0 (190.0-328.0)	317.0 (232.5-412.5)	405.0 (289.0-619.0)
Oxygen therapy**	205 (50.3%)	0 (0%)	142 (100%)	63 (100%)
Conventional oxygen therapy	205 (50.3%)	0 (0%)	142 (100%)	63 (100%)
High-flow nasal cannula	68 (16.9%)	0 (0%)	16 (11.3%)	52 (82.3%)
Mechanical ventilation	44 (11.3%)	0 (0%)	0 (0%)	44 (71.0%)
Treatment regimen				

Favipiravir	117 (30.1%)	83 (41.7%)	21 (14.8%)	13 (21.0%)
Remdesivir	233 (57.8%)	75 (37.7%)	111 (78.2%)	47 (72.3%)
Tocilizumab	17 (4.2%)	0	5 (3.5%)	12 (19.0%)
Baricitinib	7 (1.7%)	0	5 (3.5%)	2 (1.6%)
Corticosteroids	265 (66.2%)	79 (39.7%)	130 (91.5%)	56 (88.9%)
Heparin	20 (5.0%)	4 (2.0%)	9 (6.3%)	7 (11.1%)

* There were no dialysis patients.

**Not mutually exclusive ~~(i.e., more than one type of therapy could be used at the same time).~~

Data are presented as n (%) or median (interquartile range). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; WBC, white blood cell.

Table 2. Logistic regression analysis of risk factors for moderate to severe disease

Variable	Univariate analysis			Multivariate analysis		
	OR	**95% CI**	***P*-value**	**OR**	**95% CI**	***P*-value**
Patient characteristics*						
Age	1.002	0.989-1.014	0.793	-		
Female	0.684	0.458-1.019	0.062	-		
Patient habits and behaviors**						
Infection from a cluster	0.302	0.151-0.602	**<0.001**	0.312	0.152-0.639	**<0.001**
Smoking history (current- or ex-smoker)	1.635	1.069-2.502	**0.023**	1.522	0.966-2.397	0.070
Underlying disease**						
Hypertension	0.875	0.591-1.297	0.507	0.887	0.592-1.329	0.561
Cardiovascular disease	3.466	1.452-8.274	**0.005**	3.722	1.547-8.957	**0.003**
Diabetes	1.394	0.871-2.232	0.166	1.360	0.847-2.184	0.204
Dementia	0.429	0.257-0.717	**0.001**	0.367	0.210-0.641	**<0.001**
Chronic kidney disease	1.592	0.751-3.372	0.225	1.449	0.668-3.143	0.347
Underlying pulmonary condition	1.295	0.802-2.091	0.290	1.232	0.756-2.007	0.402
Malignant disease	2.021	0.845-4.835	0.114	1.924	0.796-4.651	0.146
Connective tissue disease	0.970	0.307-3.059	0.958	0.974	0.306-3.105	0.965
Symptoms at admission***						
Fever	2.788	1.499-5.187	**0.001**	2.853	1.419-5.737	**0.003**
Cough	1.285	0.866-1.906	0.213	1.279	0.815-2.007	0.285
Dyspnea	2.935	1.956-4.403	**<0.001**	2.507	1.590-3.950	**<0.001**
Sputum	1.752	0.879-3.494	0.111	1.527	0.725-3.216	0.266

Fatigue	0.957	0.631-1.450	0.835	1.002	0.629-1.595	0.995
Diarrhea	1.555	0.591-4.096	0.371	1.210	0.427-3.431	0.720
Anorexia	1.176	0.710-1.950	0.529	1.195	0.683-2.088	0.533
Laboratory data at admission**						
WBC count (per 100/μL increase)	1.016	1.008-1.024	**<0.001**	1.018	1.009-1.026	**<0.001**
Lymphocytes (per 100/μL increase)	0.970	0.936-1.006	0.103	0.975	0.943-1.007	0.126
CRP (per 1 mg/dL increase)	1.208	1.151-1.268	**<0.001**	1.183	1.125-1.243	**<0.001**
D-dimer (per 1 μg/mL increase)	1.191	1.021-1.389	**0.026**	1.254	1.046-1.505	**0.015**
Albumin (per 1 g/dL increase)	1.006	0.987-1.026	0.523	1.006	0.986-1.027	0.541
AST (per 1 IU/L increase)	1.021	1.012-1.029	**<0.001**	1.021	1.012-1.031	**<0.001**
ALT (per 1 IU/L increase)	1.010	1.004-1.017	**<0.001**	1.012	1.005-1.020	**<0.001**
LDH (per 10 IU/L increase)	1.124	1.096-1.153	**<0.001**	1.129	1.097-1.162	**<0.001**
Ferritin (per 100 ng/mL increase)	1.093	1.058-1.129	**<0.001**	1.089	1.052-1.128	**<0.001**
KL-6 (per 10 U/mL increase)	1.032	1.020-1.045	**<0.001**	1.034	1.020-1.048	**<0.001**

* No multivariate analysis was performed because variables affecting these factors were not measured.

** Since the only recorded variables that may have affected these factors, and were candidates for confounders, were the patient characteristics, multivariate analysis was conducted by adding age and sex.

*** Since the recorded variables that may have affected these factors, and were candidates for confounders, were the patient characteristics, patient habits/behaviors, and underlying disease, multivariate analysis was performed with these variables.

**** The multivariate analysis does not present a miscellaneous model with all variables entered simultaneously. Here, we present odds ratios in the model adjusted for the candidates for confounders of each variable. Please refer to * and *** for the details of the candidates for confounders.

***** We did not run multivariate analysis for age and sex because no potential confounding variables were able to be identified. However, age and sex were included in all other multivariate analyses as potential confounding variables.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; OR, odds ratio; WBC, white blood cell. Statistically significant values are in bold.

Table 3. Characteristics of patients with COVID-19: the first–third waves vs. the fourth wave (N = 404)

	First–third wave (N = 241)	Fourth wave (N = 163)	*P*-value*
Age, years	73.0 (60.0-83.0)	67.0 (52.0-76.0)	**<0.01**
Sex, female (%)	41.9%	37.4%	0.48
Infection from a cluster	39 (16.2%)	7 (4.3%)	**<0.01**
Severity			**<0.01**
Mild	145 (60.2%)	54 (33.1%)	-
Moderate	61 (25.3%)	81 (49.7%)	-
Severe	35 (14.5%)	28 (17.2%)	-
Laboratory data at admission			
WBC count (/μL)	5,700 (4,400-7,400)	5,500 (4,300-7,100)	0.24
Lymphocytes (/μL)	1,000 (700-1,200)	800 (600-1,100)	0.32
CRP (mg/dL)	4.5 (1.8-9.8)	7.4 (3.0-12.3)	**<0.01**
D-dimer (μg/mL)	1.2 (0.9-2.0)	1.4 (1.1-1.8)	0.22
Albumin (g/dL)	3.5 (3.2-3.9)	3.5 (3.2-3.8)	1.00
AST (IU/L)	34.0 (24.0-48.0)	43.5 (30.3-65.8)	**<0.01**
ALT (IU/L)	22.0 (15.0-42.0)	32.0 (18.3-58.0)	**0.04**
LDH (IU/L)	284.0 (219.0-371.0)	359.0 (272.8-452.5)	**<0.01**
Ferritin (ng/mL)	433.6 (179.4-843.2)	743.0 (386.9-1275.4)	**<0.01**
KL-6 (U/mL)	275.0 (209.0-381.0)	299.0 (222.0-405.0)	0.42
Oxygen therapy**	96 (39.8%)	109 (66.9%)	**<0.01**

Conventional oxygen therapy	96 (39.8%)	109 (66.9%)	-
High-flow nasal cannula	40 (16.6%)	28 (17.2%)	-
Mechanical ventilation	26 (10.8%)	18 (11.0%)	-
Treatment regimen			
Favipiravir	106 (44.0%)	11 (6.7%)	**<0.01**
Remdesivir	104 (43.2%)	129 (79.1%)	**<0.01**
Tocilizumab	1 (0.4%)	16 (9.8%)	**<0.01**
Baricitinib	0 (0%)	7 (4.3%)	**<0.01**
Corticosteroids	125 (51.9%)	140 (85.9%)	**<0.01**
Heparin	12 (5.0%)	8 (4.9%)	0.42
Outcome			0.80
Discharge	204 (84.6%)	140 (85.9%)	-
Transfer to the advanced hospital	24 (10.0%)	14 (8.6%)	-
Death	13 (5.4%)	9 (5.5%)	-

* Pearson's Chi-squared test, Wilcoxon rank-sum test

** Not mutually exclusive ~~(i.e., more than one type of therapy could be used at the same time).~~

Data are presented as n (%) or median (interquartile range).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; WBC, white blood cell. Statistically significant values are in bold.

Figure captions:

Figure 1. Newly diagnosed COVID-19 cases in Osaka Prefecture, Japan [5]

It had experienced four waves of infections in the COVID-19 pandemic. *The state of emergency.

Figure 2. Proportion of disease severity by age; (A) first–third waves, (B) fourth wave.

The proportion of moderate cases, particularly those in the 50–80 age group, increased.

Figure 3. Severe COVID-19 cases in Osaka Prefecture [5].

The waiting list for beds for severe patients briefly reached a maximum of 94 and they could not be transferred to the advanced hospital.



(A)



(B)





The Japanese Respiratory Society

Respiratory Investigation

Potential Conflict of Interest Disclosure Statement

Author's names: Yu Kurahara, Takehiko Kobayashi, Sayoko Shintani, Yoshinobu Matsuda, Akihiro Tamiya, Reiko Sugawara, Toru Arai, Kazunobu Tachibana, Kyoichi Okishio, Hideo Matsui, Kazunari Tsuyuguchi

Manuscript Title: Clinical Characteristics of COVID-19 in Osaka, Japan: Comparison of the First–Third Waves with the Fourth Wave

All authors are required to disclose any COI within 3 calendar years preceding the current year, prior to the submission of any manuscript in the subject matter of which any company, entity, or organization has an interest.

The corresponding author is required to complete this form with information from all the authors listed in the manuscript.

Area	No	If Yes: List the name(s) of authors and commercial entity(ies) and use as much space as necessary	
1. Employment/Leadership position/ Advisory role **(1,000,000 JPY* or more annually from one commercial entity)**	No	*e.g. Taro Fujiyama*	*e.g. ABC Pharmaceuticals*
2. Stock ownership or options **(Profit of 1,000,000 JPY or more annually from the stock of one company/ ownership of 5% or more of total shares or one company)**	No		
3. Patent royalties/licensing fees **(1,000,000 JPY or more per one royalty/licensing fee annually)**	No		

4. Honoraria (e.g. lecture fees) **(500,000 JPY or more annually from one commercial entity)**	No		
5. Manuscript fees **(500,000 JPY or more annually from one commercial entity)**	No		
6. Research funding **(1,000,000 JPY or more annually payment to departments [department, field, or laboratory] that share research expenses from the same commercial entity)*only if you can effectively determine the purpose of use .**	No		
7. Subsidies or Donations **(1,000,000 JPY or more annual payment to departments [department, field, or laboratory] that share research expenses from the same commercial entity) *only if you can effectively determine the purpose of use .**	No		
8. Endowed departments by commercial entitles (**If any of the authors belongs to an endowed department sponsored by any commercial entity**) ***only if you can effectively determine the purpose of use .**	No		
9. Travel fees, gifts, and others (**50,000JPY or more annually from one commercial entity**)	No		

*Please refer to the current currency exchange rate for Japanese Yen at an appropriate website.

This statement will be kept for 2 years after the publication of the manuscript.

Date of Completion: 01/Aug/2021

Corresponding author's Name: Kazunari Tsuyuguchi